Journey Medical (DERM)
(Delayed Data from NSDQ)
$6.17 USD
+0.42 (7.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $6.16 -0.01 (-0.16%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.17 USD
+0.42 (7.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $6.16 -0.01 (-0.16%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Molecular Templates Inc. (MTEM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Molecular Templates Inc. (MTEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Journey Medical Corporation (DERM) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Journey Medical Corporation (DERM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up
by Zacks Equity Research
Eli Lilly's (LLY) Q4 earnings and sales beat estimates. Shares rise in pre-market trading.
Lilly (LLY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with older products lead to an earnings beat for the company.
Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate
by Zacks Equity Research
Lilly (LLY) offers to buy Dermira for $1.1 billion to add the latter's late-stage candidate for atopic dermatitis/eczema, lebrikizumab.
The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences
Buy Multibagger Stocks as Odds of a Rally Are High in 2020
by Tirthankar Chakraborty
Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.
Pacira's (PCRX) Exparel Meets Key Goals in C-Section Study
by Zacks Equity Research
Pacira's (PCRX) phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section attains the primary as well as key secondary endpoints.
Moving Average Crossover Alert: Dermira
by Zacks Equity Research
Dermira, Inc. (DERM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Will Dermira Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Dermira.
The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co
by Zacks Equity Research
The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co
Pharma Sector Tops in October: Best ETFs & Stocks
by Sanghamitra Saha
Pharma sector wins in October, making these ETFs and stocks winners.
Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks
by Zacks Equity Research
The healthcare sector seems to be least affected by a protracted U.S.-China trade war. Stellar third-quarter earnings make the sector a hotbed for money.
Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats third-quarter 2019 earnings and revenue estimates and raises its guidance for 2019.
Dermira (DERM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dermira (DERM) delivered earnings and revenue surprises of 24.29% and 4.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Divests Rhofade to EPI Health for $55M, Shares Up
by Zacks Equity Research
Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.
Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study
by Zacks Equity Research
Dermira (DERM) starts a phase III program for evaluation of its monoclonal antibody candidate, lebrikizumab, in adolescents and adult patients with atopic dermatitis, the most common form of eczema.
Dermira (DERM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dermira (DERM) delivered earnings and revenue surprises of 63.33% and 95.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Dermira (DERM) Q2 Earnings Expected to Decline
by Zacks Equity Research
Dermira (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dermira (DERM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dermira (DERM) delivered earnings and revenue surprises of -13.74% and -6.77%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Dermira (DERM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Dermira (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dermira (DERM) Catches Eye: Stock Jumps 12%
by Zacks Equity Research
Dermira (DERM) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.
Company News For Mar 19, 2019
by Zacks Equity Research
Companies in the news are: OSTK, FIS, WP, EW and DERM
Implied Volatility Surging for Dermira (DERM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Dermira (DERM) stock based on the movements in the options market lately.
Dermira (DERM) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dermira (DERM) delivered earnings and revenue surprises of 20.20% and -10.38%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?